BEIJING, July 19 (Xinhua) -- Sichuan Huiyu Pharmaceutical Co., Ltd (688553. SH) announced recently that its docetaxel injection and paclitaxel injection have been approved by the Turkmenistan food and drug watchdog to go on sale.
Docetaxel injections are used for treating head and neck cancer, pancreatic cancer, gastric cancer, melanoma, and soft tissue sarcoma, while paclitaxel injections deal with ovarian cancer, breast cancer, advanced non-small cell lung cancer, and AIDS-related Kaposi sarcoma.
The two products mark the company's debut in the Turkmenistan market, which is an important part of its global strategy.
According to the company, having the two injections sold in Turkmenistan helps build up its brand image, expand business overseas, and lay a solid foundation for its international development. (Edited by Wu Rui, hupingchao@xinhua.org)
A single purchase
